Symptomatic treatment only

PreclinicalSmall molecule

BBeni-Suef University

Symptomatic treatment only is one of 12 small molecule programs targeting Mucositis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MucositisActive, not recruiting

MucositisPreclinical

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Mucositis

#DrugCompanyPhaseTrials

Galzin

AAmerican Regent, Inc.

Approved

1 2

Tylenol

KKenvue Brands

Approved

—3

Kenalog

BBausch Health Americas, Inc.

Approved

—4

Ethyol

LLegacy Health System

Approved

—5

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

—6

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

—7

N-Acetylcysteine /tab

FFar Eastern Memorial Hospital

Phase 3

1 8

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Peridex

DDexcel Pharma Technologies Ltd.

Preclinical

1 10

Kepivance

SSwedish Orphan Biovitrum

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mucositis1 trial

Adjunctive Treatments for the Prevention of Radiotherapy-Induced Mucositis

Completed·—·N/A·NCT06117904·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Symptomatic treatment only. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Symptomatic treatment only compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Symptomatic treatment only. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beni-Suef University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBeni-Suef University

Symptomatic treatment only

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mucositis1 trial

References

Drug Info

Quick Facts

Related News